Memphasys Limited (ASX:MEM)

Market Cap	24.70M +176.7%
Revenue (ttm)	213.98K +52.1%
Net Income	-4.41M
EPS	-0.00
Shares Out	3.09B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,240,884
Open	0.0070
Previous Close	0.0080
Day's Range	0.0070 - 0.0080
52-Week Range	0.0030 - 0.0080
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage p...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 24
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MEM

Financial Performance

In fiscal year 2025, Memphasys's revenue was 526,921, an increase of 237.77% compared to the previous year's 156,000. Losses were -5.04 million, -6.19% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 17, 2026

Data Sources Report a data error